Related Experiment Video
Updated: Dec 17, 2025
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.0K
Metformin use in prediabetes: is earlier intervention better?
Andrew Warrilow1, Shawn Somerset2, Kate Pumpa2
1University of Canberra, Locked Bag 1, Canberra, ACT, 2601, Australia. andrew.warrilow@canberra.edu.au.
Acta Diabetologica
|July 1, 2020
Summary
Metformin effectively prevents type 2 diabetes in prediabetic individuals, especially those with higher fasting plasma glucose (FPG) and more pronounced impaired fasting glucose (IFG). It also helps stabilize insulin sensitivity.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Prediabetes is a significant risk factor for developing type 2 diabetes.
- Early intervention strategies are crucial for diabetes prevention.
- Metformin is a commonly used medication for type 2 diabetes management.
Purpose of the Study:
- To evaluate metformin's efficacy in preventing diabetes in prediabetic individuals across varying fasting plasma glucose (FPG) levels.
- To determine if metformin is more effective in preventing diabetes in those with impaired fasting glucose (IFG) compared to impaired glucose tolerance (IGT).
Main Methods:
- Analysis of participants from the Diabetes Prevention Program study, stratified by baseline FPG levels.
- Assessment of cumulative diabetes incidence, changes in FPG, insulin sensitivity, fasting insulin, and proinsulin levels.
- Comparison of metformin's effects between different prediabetic sub-cohorts.
Main Results:
- Metformin demonstrated the greatest reduction in diabetes incidence and FPG in prediabetic individuals with higher baseline FPG.
- Metformin stabilized insulin sensitivity in most sub-cohorts.
- Diabetes incidence was reduced by 43% in those with more pronounced IFG, versus 26% overall.
Conclusions:
- Higher baseline FPG levels in prediabetic individuals correlate with greater diabetes incidence reduction by metformin.
- Metformin is effective in stabilizing insulin sensitivity and shows enhanced efficacy in individuals with more pronounced IFG.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
514
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
514
01:06Oral Hypoglycemic Agents: Glinides
485
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
485
01:23Dipeptidyl Peptidase 4 Inhibitors
460
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
460
01:15Diabetes: Management and Pharmacotherapy
772
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
772
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
443
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
443
01:22Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K